Subcutaneously administered Menopur(R) a new highly purified human menopausal gonadotropin causes significantly fewer injection site reactions than Repronex(R) in subjects undergoing in vitro fertilization

摘要

BackgroundThe safety and tolerability of a new highly purified, urine-derived human menopausal gonadotropin (hMG) preparation [Menopur(R)] was compared with a currently available hMG [Repronex (R)] in women undergoing in vitro fertilization (IVF).